Table 4.
Means and Standard Deviations of Treatment Beliefs, and Attendance Between Racial Groups (N = 173)
| Measures | African Americans (n =43) | Caucasians (n =130) | t | d |
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | |||
| PE | ||||
| Treatment Credibility (CS) | 37.77 (7.41) | 37.03 (6.96) | 0.57 | 0.10 |
| Reaction to Rationale (PRR) | 27.72 (6.30) | 26.94 (6.27) | 0.71 | 0.12 |
| Outcome Expectancy (ETO) | 24.16 (6.61) | 23.64 (6.63) | 0.38 | 0.08 |
| Sessions attended | 5.67 (4.02) | 7.97 (3.41) | −2.54* | 0.87 |
| Early alliance (WAI) | 73.12 (18.09) | 66.78 (16.08) | 1.56 | 0.32 |
| Sertraline | ||||
| Treatment Credibility (CS) | 34.77 (8.39) | 34.15 (8.44) | 0.42 | 0.07 |
| Reaction to Rationale (PRR) | 23.49 (9.27) | 20.84 (7.46) | 1.89 | 0.31 |
| Outcome Expectancy (ETO) | 24.42 (6.63) | 22.00 (7.35) | 1.21 | 0.35 |
| Sessions attended | 5.05 (3.47) | 7.19 (3.59) | −2.25* | 0.53 |
| Early alliance (WAI) | 64.71 (20.23) | 62.20 (17.14) | 0.51 | 0.12 |
Note. PE: Prolonged Exposure; CS = Credibility Scale; PRR = Personal Reactions to Rationale; ETO = Expectancy of Therapeutic Outcome; WAI = Working Alliance Inventory (Client Rated) at Sessions 2 and 4.
CS and PRR completed at randomization visit; ETO completed at session 1.
*
p < .05